Genetic causes of PD: A pathway to disease modification
- 29 February 2020
- journal article
- review article
- Published by Elsevier BV in Neuropharmacology
- Vol. 170, 108022
- https://doi.org/10.1016/j.neuropharm.2020.108022
Abstract
No abstract availableFunding Information
- Medical Research Council (MR/J009660/1)
- Royal Free Hospital Charity
- Parkinson’s UK (G-1704)
- UCLH National Institute for Health Research (NF-SI-0611-10237)
This publication has 172 references indexed in Scilit:
- Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic casesNeurobiology of Disease, 2013
- Fibrillar α-Synuclein and Huntingtin Exon 1 Assemblies Are Toxic to the CellsBiophysical Journal, 2012
- Glucocerebrosidase deficiency in substantia nigra of parkinson disease brainsAnnals of Neurology, 2012
- Characterization of TAE684 as a potent LRRK2 kinase inhibitorBioorganic & Medicinal Chemistry Letters, 2012
- Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron DeathNeuron, 2011
- VPS35 Mutations in Parkinson DiseaseAmerican Journal of Human Genetics, 2011
- Gaucher Disease Glucocerebrosidase and α-Synuclein Form a Bidirectional Pathogenic Loop in SynucleinopathiesCell, 2011
- Identification of compounds that inhibit the kinase activity of leucine-rich repeat kinase 2Biochemical and Biophysical Research Communications, 2009
- Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control studyThe Lancet Neurology, 2008
- α-synuclein locus duplication as a cause of familial Parkinson's diseaseThe Lancet, 2004